2015.8.9. 271PPA 1
MDS M0 M4 M6 Leukemia(AML) CFU-GM CNL M1 M2 M3 M5 FAB 19821994 Revised Rappaport s/who/lukes-collins/kiel 1976 Working Formulation (WF) 1982~1988 REAL 1994 CML CFU-GEMM stem cell M7 undifferentiated ALL Leukemia(ALL) BFU-E CFU-Meg Common ALL pre-pre-b pre-b immature B mature B B B pre-t pret-all early-t T-ALL Lymphoma common-t CLL CLL Myeloma WHO Jaffe ES et al 2001 / 200810 Ver.4
VIII FS IX DNA,RNA
<1> DNA DNA 6-2) DNA <2>. SIADH (40%) WBCMPO t(8;21), inv(16),t(15;17) (70%) t(15;17) M3 :(A) ( 4050%) FLT3-ITD NPM1 <3> L- L- JALSG ALL93 33% Clonal evoluon Ph de novo
(5-Year 93%) IFN or SCT 2 nd line (5-Year 71%) 2nd TKI ImatinibABL NEJM 3542542-2551, 2006 Srcscreening ATP Imatinib Imatinib325 NEJM 3542531-2541, 2006 ABL TKI T315I IFN: SCT IFN or SCT (5-Year 63%) IFN (5-Year 53%) (5-Year 38%) TKI 3rd TKI Abl, Src T315IV299L Type 1 Type 2 16
M3g/dl 10 And No Yes 4 1960 200810 TERMS 26S IBNF-B Immunomodulatory drugs (IMiDs) 20107 RevMate Immunomodulatory drugs (IMiDs) 200610 20153 Kumar SK. et al. Blood 2008; 111: 2516-2520 CD20) C5 CCR4 IL6 CD33 CD30 calicheamicin CD20 CD30 CD20 MMAE CD30 internalization CD33 CD33 ALCL
. 20019 Pathol Int 2000;50:696-702. PNH anti-cd20 McAb - 90 Y Ibritumomab Tiuxetan (Zevalin ) 2008 Coiffier B et al. N Engl J Med 2002;346:235-242 10 Blood 2010; 116:2040-2045 43.5% 24.6%
. Flower Cells AZT CCR4 1977 1985 1990 2015~ () 1983 19861991 2010
R-CHOP Day 1 2 3 4 5 6 Rituximab 375 mg/m 2 (div) CY 750 mg/m 2 (div) DXR 50 mg/m 2 (div) VCR 1.4 mg/m 2 (max 2mg) (iv) PSL 100 mg/body (po) PEG-G-CSF 25 PEG Metcalf D., Nature 1994;364:519 TPOexonintron 3q27-28 ~70kDa 332 ( Malignant mesothelioma (Plt=170) IL-6 Stem Cells 16: 322-328, 1998 Higashihara M, et al: Cancer 70: 2105-2108, 1992
TPO TPO P SHC GRB2 P SOS RAS/RAF PI3K STAT P P JAK MAPKK AKT p42/44 J. Cell Biol. 147:1299, 1999 WF ITP Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood 2009;113: 2386 --------------------------------------------------------------------------------------------- Idiopathic (immune) Thrombocytopenic Purpura (ITP) Immune Purpura Immune Thrombocytopenia (ITP) primary secondary i.e. secondary ITP(lupus-associated) lupus-associated ITP
2004~2007 7,774 130 56 Kurata Y, et al. Int J Hematol 93:329, 2011 1. 22,853 2. 9,479 3. 1,192 2012 53:433-42, 2012 ITP Increased platelet destruction () Anti-platelet immunity Antimegakaryocyte immunity Decreased platelet production () ~60kD mplfc NEJM 355:1672, 2006
A Romiplostim Kumagai Y, et al. J Clin Pharmacol 2007;47(12):1489-97. 0.3, 1, 2μg/kg 1μg/kg 1μg/kg 4/81.52μg/kg 3/81.53/82 TPO(2005 ) 20101228 Shirasugi Y, et al. Int J Hematol, 2009 3 Miyazaki K, et al. (ASH, 2010; EHA, 2011 ) Shirasugi Y, et al. Int J Hematol 2011; 2012 1~10μg/kg ic 2011121 2008 2012 53:433-42, 2012 12.5~50mg/body : 546 20101210 2008 ITP H.Pylori(+) H.Pylori(-) H.Pylori First line Second line Third line
2010618ITP 3 H.Pylori 2. Metronidazole 500mg 2x 2005 69%(300/435) 63%(103/163) ( 48